清肺口服液联合喜炎平注射液治疗小儿博卡病毒肺炎的临床研究
|
摘要
目的观察清肺口服液联合喜炎平注射液治疗小儿博卡病毒肺炎的临床疗效。方法将59例博卡病毒肺炎患儿随机分为治疗组与对照组,治疗组采用清肺口服液联合喜炎平注射液治疗,对照组给予氨溴特罗口服液和利巴韦林注射液治疗,观察两组患儿的综合疗效,及治疗前后主症积分、次症积分和症状总积分变化情况。结果治疗组综合疗效优于对照组(P<0.05);两组治疗后主症积分、次症积分、症状总积分均较治疗前降低(P<0.05);在治疗后主症积分、次症积分和症状总积分下降方面,治疗组优于对照组(P<0.05)。结论清肺口服液联合喜炎平注射液治疗小儿博卡病毒肺炎疗效确切。
Objective To observe the clinical effect of Qingfei Oral Liqulid and Xiyanping Injection in the treatment of children with human bocavirus pneumonia. Methods Children with human bocavirus pneumonia(59 cases) were randomly divided into treatment group and control group. The cases in the treatment group were treated with Qingfei Oral Liqulid and Xiyanping Injection, and those in the control group were given Ambroxol and Clenbuterol oral solution and Ribavirin injection. The comprehensive efficacy, before and after treatment of primary symptoms scores, secondary symptoms scores, and total scores of symptoms were observed. Results The treatment group had superior comprehensive efficacy over the control group(P < 0.05). Both groups had reduced scores for primary symptoms and secondary symptoms and total scores for symptoms after treatment(P < 0.05). The decreases in the scores for primary symptoms and secondary symptoms and the total scores for symptoms after treatment were larger in the treatment group than those in the control group(P < 0.05). Conclusion Qingfei Oral Liqulid and Xiyanping Injection had definitive efficacy in the treatment of human bocavirus pneumonia in children.
Objective To observe the clinical effect of Qingfei Oral Liqulid and Xiyanping Injection in the treatment of children with human bocavirus pneumonia. Methods Children with human bocavirus pneumonia(59 cases) were randomly divided into treatment group and control group. The cases in the treatment group were treated with Qingfei Oral Liqulid and Xiyanping Injection, and those in the control group were given Ambroxol and Clenbuterol oral solution and Ribavirin injection. The comprehensive efficacy, before and after treatment of primary symptoms scores, secondary symptoms scores, and total scores of symptoms were observed. Results The treatment group had superior comprehensive efficacy over the control group(P < 0.05). Both groups had reduced scores for primary symptoms and secondary symptoms and total scores for symptoms after treatment(P < 0.05). The decreases in the scores for primary symptoms and secondary symptoms and the total scores for symptoms after treatment were larger in the treatment group than those in the control group(P < 0.05). Conclusion Qingfei Oral Liqulid and Xiyanping Injection had definitive efficacy in the treatment of human bocavirus pneumonia in children.
引文
[1]何霞,曹开源.人博卡病毒及其在中国的流行现状[J].病毒学报,2013,29(1):56-64.
[2]邢吴敏,韩新民.儿童感染人博卡病毒的研究进展[J].中国医药导报,2015,12(11):35-37.
[3]中华人民共和国卫生部.小儿四病防治方案(二):小儿肺炎防治方案[J].中华儿科杂志,1987,25(1):47-48.
[4]胡亚美,江载芳.诸福棠实用儿科学[M].北京:人民卫生出版社,2002.
[5]中医病证诊断疗效标准·中医儿科病证诊断疗效标准[S].1994.
[6]中药新药临床研究指导原则(试行)[S].2002.
[7]刘巧突,瞿小旺,熊波,等.从我国儿童呼吸道标本中首次检出人博卡病毒[J].实用预防医学,2007,14(1):39-41.
[8]利蓓荃,季伟,蔡利红,等.2009—2010年苏州地区博卡病毒感染住院患儿临床特征分析[J].临床儿科杂志,2012,30(8):753-756.
[9]肖霓光,张兵,段招军,等.长沙地区急性下呼吸道感染住院儿童人博卡病毒感染的初步研究[J].临床儿科杂志,2011,29(6):510-513.
[10]杨晶艳,胡鹏威,陈蕊,等.四川地区儿童呼吸道感染人博卡病毒的流行特征与基因变异分析[J].四川大学学报,2014,45(1):57-61.
[11]吴方,余陈欢,俞文英,等.基于micro RNAs的石荠苧总黄酮抗流感病毒性肺炎作用机制研究[J].中草药,2016,47(7):1149-1154.
[12]孟欣,汪受传,单进军,等.基于GC-MS的金欣口服液对RSV肺炎小鼠脾脏代谢物的调控作用[J].中草药,2016,47(24):4408-4415.
[13]王昕泰,谢辉辉,徐珊.清肺口服液治疗儿童病毒性肺炎疗效及安全性的Meta分析[J].时珍国医国药,2015,26(12):3054-3058.
[14]王飞,陈静,康定理,等.喜炎平注射液联合氨溴特罗口服溶液治疗小儿支气管肺炎的疗效观察[J].现代药物与临床,2016,31(9):1423-1426.
[15]唐军.喜炎平注射液在儿科的应用进展[J].临床合理用药,2012,5(7C):162-163.
[16]田小燕,李元霞.利巴韦林和喜炎平联合治疗小儿轻度手足口病的效果分析[J].药物评价研究,2015,38(4):409-412.
[17]王伟,董国力.喜炎平注射液的临床研究进展[J].中国医药指南,2013,11(18):87-88.
[18]严华杰,盛军,董蔚,等.上海嘉定地区连续3年儿童人博卡病毒感染的研究[J].临床儿科杂志,2010,28(6):549-551.
[2]邢吴敏,韩新民.儿童感染人博卡病毒的研究进展[J].中国医药导报,2015,12(11):35-37.
[3]中华人民共和国卫生部.小儿四病防治方案(二):小儿肺炎防治方案[J].中华儿科杂志,1987,25(1):47-48.
[4]胡亚美,江载芳.诸福棠实用儿科学[M].北京:人民卫生出版社,2002.
[5]中医病证诊断疗效标准·中医儿科病证诊断疗效标准[S].1994.
[6]中药新药临床研究指导原则(试行)[S].2002.
[7]刘巧突,瞿小旺,熊波,等.从我国儿童呼吸道标本中首次检出人博卡病毒[J].实用预防医学,2007,14(1):39-41.
[8]利蓓荃,季伟,蔡利红,等.2009—2010年苏州地区博卡病毒感染住院患儿临床特征分析[J].临床儿科杂志,2012,30(8):753-756.
[9]肖霓光,张兵,段招军,等.长沙地区急性下呼吸道感染住院儿童人博卡病毒感染的初步研究[J].临床儿科杂志,2011,29(6):510-513.
[10]杨晶艳,胡鹏威,陈蕊,等.四川地区儿童呼吸道感染人博卡病毒的流行特征与基因变异分析[J].四川大学学报,2014,45(1):57-61.
[11]吴方,余陈欢,俞文英,等.基于micro RNAs的石荠苧总黄酮抗流感病毒性肺炎作用机制研究[J].中草药,2016,47(7):1149-1154.
[12]孟欣,汪受传,单进军,等.基于GC-MS的金欣口服液对RSV肺炎小鼠脾脏代谢物的调控作用[J].中草药,2016,47(24):4408-4415.
[13]王昕泰,谢辉辉,徐珊.清肺口服液治疗儿童病毒性肺炎疗效及安全性的Meta分析[J].时珍国医国药,2015,26(12):3054-3058.
[14]王飞,陈静,康定理,等.喜炎平注射液联合氨溴特罗口服溶液治疗小儿支气管肺炎的疗效观察[J].现代药物与临床,2016,31(9):1423-1426.
[15]唐军.喜炎平注射液在儿科的应用进展[J].临床合理用药,2012,5(7C):162-163.
[16]田小燕,李元霞.利巴韦林和喜炎平联合治疗小儿轻度手足口病的效果分析[J].药物评价研究,2015,38(4):409-412.
[17]王伟,董国力.喜炎平注射液的临床研究进展[J].中国医药指南,2013,11(18):87-88.
[18]严华杰,盛军,董蔚,等.上海嘉定地区连续3年儿童人博卡病毒感染的研究[J].临床儿科杂志,2010,28(6):549-551.